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Abstract
The NMDA receptors (NMDARs) expressed by AII and A17 amacrine cells, the 
two main inhibitory interneurons of the rod pathway microcircuit in the mamma-
lian retina, are exclusively extrasynaptic, activated by ambient levels of glutamate, 
and molecularly distinct, with AII and A17 amacrines expressing GluN2B- and 
GluN2A- containing receptors, respectively. This important sensory microcircuit 
thus provides a unique model to study the activation and function of extrasynaptic 
NMDARs. Here, we investigated the sources of glutamate and the endogenous co- 
agonists (d- serine or glycine) that activate these distinct populations of NMDARs. 
With acute slices from rat retina, we used whole- cell voltage- clamp recording and 
measurement of current noise to monitor levels of NMDAR activity. Pre- incubation 
of retina with bafilomycin A1 (an inhibitor of neurotransmitter uptake into synaptic 
vesicles) abolished NMDAR- mediated noise in AII, but not A17 amacrines, suggest-
ing a vesicular source of glutamate activates AII NMDARs, whereas a non- vesicular 
source activates A17 NMDARs. Pre- incubation of retina with l- methionine sulfoxi-
mine (an inhibitor of glutamine synthetase) also abolished NMDAR- mediated noise 
in AII, but not A17 amacrines, suggesting a neuronal source of glutamate activates 
AII NMDARs, whereas a glial source activates A17 NMDARs. Enzymatic break-
down of d- serine reduced NMDAR- mediated noise in AII, but not A17 amacrines, 
suggesting d- serine is the endogenous co- agonist at AII, but not A17 NMDARs. 
Our results reveal unique characteristics of these two populations of extrasynaptic 
NMDARs. The differential and independent activation of these receptors is likely to 
provide specific contributions to the signal processing and plasticity of the cellular 
components of the rod pathway microcircuit.
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1 |  INTRODUCTION
Fast chemical signaling between neurons occurs at mor-
phologically specialized points of contact called synapses, 
generally containing a high density of neurotransmitter re-
ceptors (Cowan & Kandel, 2001). It is clear, however, that 
neuronal function can be modulated by the activation of so- 
called extrasynaptic receptors, located away from the synapse 
(Rusakov & Dityatev, 2014). Extrasynaptic receptors can be 
involved in volume transmission, where neurotransmitter is 
released from presynaptic structures with no directly apposed 
postsynaptic target (Fuxe et al., 2007), or can be activated by 
neurotransmitter spilling out from the synaptic cleft after re-
lease at conventional synapses (Barbour & Häusser, 1997). It 
has been speculated that the molecular composition of synap-
tic and extrasynaptic receptors for the same neurotransmitter 
differ, most likely as an adaptation to differences in magni-
tude and temporal profile of the neurotransmitter concentra-
tion (Muller et al., 2008).
Among ionotropic glutamate receptors, there is evidence 
that NMDA receptors (NMDARs) can be involved in both 
synaptic and extrasynaptic neurotransmission (Paoletti 
et al., 2013; Papouin & Oliet, 2014). It has been suggested 
that GluN2A subunit- containing receptors primarily have a 
synaptic location (e.g., Dalby & Mody, 2003) and GluN2B 
subunit- containing receptors primarily have an extrasynaptic 
location (e.g., Scimemi et al., 2004). Irrespective of location, 
the precise subunit composition of NMDARs is of interest be-
cause it determines functional properties such as affinity for 
agonists and co- agonists, single- channel conductance, open 
probability, kinetics, sensitivity to Mg2+, and magnitude of 
Ca2+ permeability (Monyer et al., 1994; Paoletti et al., 2013). 
NMDARs are unique in that channel gating requires simul-
taneous binding of two different ligands, that is, glutamate 
and a co- agonist (glycine or d- serine), as well as coincident 
depolarization of the cell membrane to relieve Mg2+ block of 
the channel (Traynelis et al., 2010). In this way, NMDARs 
function as both ligand- and voltage- gated ion channels, and 
their high Ca2+ permeability allows for an influx of Ca2+ 
that triggers intracellular events, including those related to 
normal physiological functions such as long- lasting synap-
tic plasticity, as well as paradoxically, excitotoxicity, and cell 
death (Paoletti et al., 2013; Papouin & Oliet, 2014). The ex-
istence of two different NMDAR co- agonists, glycine, and d- 
serine, both of which can be present in neural tissue, has lead 
to the search for the identity and source of the endogenous 
co- agonist that is involved with specific NMDARs in specific 
neural circuits (Hansen et al., 2018). Although there are only 
minor differences between the co- agonists with respect to af-
finity for NMDARs, the temporal and spatial availability of 
co- agonist may be a limiting factor for activation of specific 
NMDARs (Mothet et al., 2015).
In the retina, inhibitory transmission in the rod pathway 
primarily involves two types of interneurons, AII and A17 
amacrine cells, both of which express NMDARs (Hartveit & 
Veruki, 1997; Veruki et al., 2019; Zhou et al., 2016). AIIs and 
A17s receive common glutamatergic input from rod bipolar 
cells at dyad synapses in the proximal inner plexiform layer 
(Kolb & Famiglietti,  1974; Nelson & Kolb,  1985; Strettoi 
et al., 1990, 1992). The AII also receives glutamatergic input 
from OFF- cone bipolar cells at its lobular dendrites in the dis-
tal inner plexiform layer (Strettoi et al., 1992). Recent work 
in our laboratory has suggested that the NMDARs on AII and 
A17 amacrines are molecularly distinct, containing either 
GluN2B or GluN2A subunits, respectively, and, for both cell 
types, these receptors are exclusively extrasynaptic and ac-
tivated by ambient levels of glutamate (Veruki et al., 2019).
Here, we investigated the sources of glutamate and the 
identity of the endogenous co- agonists that activate AII and 
A17 NMDARs. Our results suggest that the glutamate that 
activates NMDARs on AII amacrines originates from spill-
over following vesicular (i.e., exocytotic) release from neu-
rons. In contrast, for NMDARs on A17 amacrines, the source 
of glutamate is non- vesicular, most likely from glial cells. 
Additionally, our results suggest that d- serine is the primary 
endogenous co- agonist at NMDARs of AII amacrines, but 
not at NMDARs of A17 amacrines. That these two extrasyn-
aptic receptor populations are activated by glutamate derived 
from different sources and released by distinct mechanisms, 
as well as by different endogenous co- agonists, suggests that 
each population is able to provide a distinct contribution to 
excitability and signaling in this microcircuit.
2 |  MATERIALS AND METHODS
2.1 | Retinal slice preparation and visual 
targeting of neurons
General aspects of the methods have previously been de-
scribed in detail (Veruki et al., 2019). The use of animals in 
this study was carried out under the approval of and in accord-
ance with the regulations of the Animal Laboratory Facility 
at the Faculty of Medicine at the University of Bergen (ac-
credited by AAALAC International). Female and male rats 
(Wistar HanTac; 4– 7 weeks postnatal; bred in- house or from 
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Taconic Bioscience, Denmark) had ad libitum access to food 
and water and were kept on a 12/12 light/dark cycle. Animals 
were deeply anaesthetized with isoflurane (IsoFlo vet 100%; 
Abbott Laboratories) in 100% O2 and killed by cervical dis-
location. After dissection, each retina was cut into four pieces 
and stored in an interface chamber containing Ames' solu-
tion (Sigma- Aldrich) supplemented with 25- mM NaHCO3 to 
control for pH and bubbled with gas containing 5% CO2 and 
95% O2. Vertical slices were cut by hand at ~100 to ~150 µm 
and visualized using an Axioskop 2 FS (Zeiss) with a ×40 
water immersion objective and infrared differential interfer-
ence contrast (IR- DIC) videomicroscopy.
2.2 | Solutions and drugs
The standard extracellular perfusing solution was continu-
ously bubbled with 95% O2– 5% CO2 and had the following 
composition (in mM): 125 NaCl, 25 NaHCO3, 2.5 KCl, 2.5 
CaCl2, 1 MgCl2, 10 glucose, pH 7.4. To permit observation 
of NMDAR activity at negative holding potentials, MgCl2 
was omitted from the extracellular solution with no replace-
ment of divalent cations (referred to later as Mg2+- free bath 
solution) to relieve the voltage- dependent block of NMDARs 
(Nowak et al., 1984). For these recordings, we switched to 
the Mg2+- free solution at least 10 min before establishing the 
whole- cell recording configuration for each cell. d- serine, a 
co- agonist of NMDARs (Kleckner & Dingledine, 1988), was 
added to the extracellular solution (100 µM; Sigma- Aldrich) 
as indicated, to either test for saturation of co- agonist bind-
ing or ensure adequate levels of co- agonist in the presence 
of α- amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic acid 
(AMPA) receptor blockers that can reduce the release of 
d- serine in the retina (Stevens et  al.,  2003; Sullivan & 
Miller, 2012).
Recording pipettes were filled with (in mM): 125 
CsCH3SO3, 8 NaCl, 10 HEPES, 1 CaCl2, 5 EGTA, 15 
TEA- Cl, 4  Mg- ATP (pH adjusted to 7.3 with CsOH). For 
visualization of complete cellular morphologies with flu-
orescence microscopy after the recording, Alexa Fluor 594 
(40 µM; Invitrogen/Thermo Fisher Scientific) was included 
in the intracellular solution. Drugs were added directly to 
the extracellular solution at the following concentrations 
(supplied by Hello Bio, unless otherwise indicated): 1- µM 
strychnine (Research Biochemicals International); 10- µM 
(−)- bicuculline methochloride (Tocris Bioscience); 0.3- or 
1- µM tetrodotoxin (TTX); 10- µM 6- cyano- 7- nitroquinoxali
ne- 2,3- dione (CNQX); 20- µM (RS)- 3- (2- carboxypiperazin- 
4- yl)- propyl- 1- phosphonic acid (CPP); 50- µM 0.05 dl- 
threo- β- benzyloxyaspartic acid TBOA; 0.29  U/ml d- amino 
acid oxidase (DAAO; Merck). DAAO was perfused for at 
least 20 min before measurements were made (cf. Kalbaugh 
et al., 2009).
For some experiments, prior to cutting slices and elec-
trophysiological recording, pieces of retina were incubated 
by submersion for 2.5– 4  hr in a small volume (~1  ml) of 
Ames' solution (with 25- mM NaHCO3 to control for pH and 
bubbled with 5% CO2 and 95% O2) and either 4- µM bafi-
lomycin A1 (henceforth referred to as bafilomycin; Hello 
Bio) or 5- mM l- methionine sulfoximine (MSO; Sigma- 
Aldrich). Bafilomycin was first dissolved in dimethyl sulf-
oxide (DMSO; Sigma- Aldrich) at a concentration of 1 mM 
before dilution to the final concentration in Ames' solution. 
As a control, we incubated retina tissue in Ames' solution (as 
above) with 0.4% DMSO (equal to the final concentration of 
DMSO in the solution with bafilomycin).
2.3 | Electrophysiological recording, data 
acquisition, and imaging
Patch pipettes were pulled from thick- walled borosilicate 
glass (BF150- 86– 10; Sutter Instrument) to obtain an open- 
tip resistance that ranged from 5 to 8 MΩ when filled with 
intracellular solution. Whole- cell voltage- clamp recordings 
were performed with an EPC9- dual amplifier controlled with 
Patchmaster software (HEKA Elektronik). The data acquisi-
tion software corrected all holding potentials (Vh) for liquid 
junction potentials on- line. Theoretical liquid junction po-
tentials were calculated with JPCalcW (Axon Instruments). 
In all experiments, AII and A17 amacrine cells were held 
at a membrane potential of −60 or −70  mV, respectively. 
For whole- cell recordings, series resistance (Rs) was moni-
tored throughout the recording (for details, see Castilho 
et al., 2015). Cells with Rs > 45 MΩ were not included in the 
final material.
To examine NMDAR activity and the influence of differ-
ent pharmacological manipulations, we measured membrane 
current noise, that is, the variance of the current recorded in 
the whole- cell voltage- clamp configuration (Sah et al., 1989; 
Veruki et al., 2019). Current variance was calculated for 20- s 
epochs of continuous recording interrupted by intervals of 
~15  s where we sampled responses for calculating Rs. The 
variance from two to four such epochs was averaged for any 
given condition. The sampling interval was set to 500 µs, and 
the corner frequency (−3 dB) of the low- pass filter was set 
to 952.4  Hz (Butterworth), corresponding to a ratio of 2.1 
between the sampling and corner frequencies (for details, see 
Veruki et al., 2019).
In some cases, image stacks of amacrine cells filled with 
fluorescent dye were acquired using a digital CCD camera 
(CoolSnap ES; Photometrics/Roper Scientific) controlled by 
µManager software (www.micro - manag er.org) running under 
Windows XP. During image acquisition, exposure to UV 
light was controlled by an electronic shutter (Uniblitz VCM- 
D1, Vincent Associates) to minimize the total exposure time. 
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Deconvolution of image stacks and generation of maximum 
intensity projections were performed as described in Zandt 
et  al.  (2017). Final adjustments of contrast and brightness 
were applied homogeneously over the entire image.
2.4 | Experimental design and 
statistical analysis
Electrophysiological data were analyzed with Fitmaster 
(HEKA Elektronik), IGOR Pro (WaveMetrics), and Excel 
(Microsoft). Data are presented as mean ± SEM (n = num-
ber of cells) with ranges either displayed by individual data 
points in bar graphs or stated explicitly. We did not perform 
prior sample size calculations for these experiments, which 
are relatively time- consuming and difficult to perform. 
Instead, each cell served as its own control and we used all 
the cells from which we obtained high- quality recordings, 
within a reasonable time frame, making sure that each cell 
type was covered by at least three cells for each experiment. 
Statistical analyses were performed in Prism 6 (GraphPad 
Software) using ratio paired t tests (two- tailed) or ANOVA 
(one- way or two- way), as indicated. The ratio paired t test is 
appropriate when there is reason to believe that the relative 
difference is a more consistent measure than the absolute dif-
ference. Differences were considered statistically significant 
at the p < 0.05 level. Exact p values are given in the text or in 
the figure legends. Unless otherwise noted, the current traces 
shown in the figures represent individual traces. Altogether, 
recordings from 25 AII and 32 A17 amacrine cells are pre-
sented, including four A17 amacrine cells tested with TBOA 
(originally published in Veruki et  al.,  2019) that were re- 
analyzed and compared with the A17 amacrines tested with 
TBOA after incubation in MSO.
F I G U R E  1  Identification of AII and A17 amacrine cells in the rat retinal slice. (a) IR- DIC videomicrograph of a retinal slice with cell body 
(arrow) and apical dendrite of an AII amacrine. Here and in (b), the retinal layers are indicated by abbreviations and the borders between layers 
are marked by lines aligned with their orientation (ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner 
plexiform layer). (b) IR- DIC videomicrograph of a retinal slice with cell body of an A17 amacrine (with pipette attached). Scale bar: (a, b) 10 µm. 
(c) Electrophysiological “signature” of AII amacrine cell during whole- cell voltage- clamp recording. Transient inward currents (bottom traces) 
correspond to unclamped action currents (escape from voltage clamp) evoked by 5 mV depolarizing voltage pulses from Vh = −60 mV (top trace). 
(d) Wide- field fluorescence image of AII amacrine filled with Alexa 594 via patch pipette, maximum intensity projection of image stack after 
deconvolution. Scale bar: 10 µm. (e) Wide- field fluorescence image of A17 amacrine filled with Alexa 594 via patch pipette, maximum intensity 
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3 |  RESULTS
3.1 | Identification of AII and A17 amacrine 
cells in retinal slices
Both AII and A17 amacrine cells can be visually targeted in 
the retinal slice. The primary targeting criterion was the shape 
and location of the cell bodies at the border between the inner 
nuclear layer and the inner plexiform layer (Figure 1a,b). The 
AII amacrine has an elongated cell body that spans the bor-
der between the inner nuclear layer and the inner plexiform 
layer and a thick apical dendrite that tapers as it descends 
into the inner plexiform layer (Figure  1a). In contrast, the 
A17 amacrine has a dome- shaped cell body, with the flat sur-
face located at the border between the inner nuclear layer and 
the inner plexiform layer (Figure 1b). Following establish-
ment of the whole- cell configuration for AII amacrines, we 
verified that 5- mV depolarizing pulses (from Vh = −60 mV, 
5 ms) evoked characteristic inward action currents mediated 
by TTX- sensitive voltage- gated Na+ channels (Figure  1c; 
Mørkve et al., 2002). For unequivocal identification, all re-
corded cells were visualized with fluorescence microscopy 
following the recording. The AII is a bi- stratified, narrow- 
field amacrine cell (Figure  1d), and the A17 is a diffuse, 
wide- field amacrine cell with long, thin processes that carry 
distinct varicosities and terminate near the ganglion cell layer 
of the retina (Figure 1e).
3.2 | Depletion of neurotransmitter 
from synaptic vesicles reduces activation of 
NMDARs on AII, but not A17 amacrines
We have previously demonstrated that ambient glutamate 
can activate NMDARs on both AII and A17 amacrine cells 
(Veruki et al., 2019). However, the source of this extracellular 
glutamate is not known and could be either neuronal or glial, 
or both. To differentiate between neuronal and glial sources 
of glutamate, we first examined the effect of bafilomycin, 
an inhibitor of the vacuolar ATPase that establishes the pro-
ton gradient that drives neurotransmitter uptake into synaptic 
vesicles (Dröse & Altendorf, 1997). For these experiments, 
we incubated pieces of retina in bafilomycin (4 µM) for at 
least 2.5 hr before preparing vertical slices for electrophysi-
ological recording. Because bafilomycin prevents uptake of 
neurotransmitter into synaptic vesicles, the continuous base-
line exocytosis of vesicles will effectively deplete the vesi-
cles of neurotransmitter (Cavelier & Attwell, 2007; Harrison 
& Jahr, 2003; Le Meur at al., 2007; Wu et al., 2012; Zhou 
et al., 2000).
A relatively long- lasting incubation of the retina by sub-
mersion (with bafilomycin or MSO, see below) prior to 
recording introduced a new element in our experimental 
paradigm compared with similar experiments from our lab-
oratory (cf. Veruki et al., 2019). We therefore first verified 
that NMDARs on AII and A17 amacrines could still be ac-
tivated by ambient glutamate after a similar incubation of 
tissue in control Ames' solution for the same period of time 
(at least 2.5 hr). For these experiments, CNQX, strychnine, 
bicuculline, and TTX (to block AMPA, glycine, and GABAA 
receptors and voltage- gated Na+ channels, respectively) were 
included in the bath solution during electrophysiological re-
cording. For the AII amacrine illustrated in Figure  2a, ap-
plying the NMDAR antagonist CPP markedly decreased the 
membrane current noise (measured as variance), from an 
average of 89.3 pA2 in control to 4.4 pA2 in CPP (a reduc-
tion of 95%). For a total of four AII amacrines, the average 
membrane current noise in control was 50.4 ± 20.6 pA2. This 
was reduced to 6.4 ± 2.2 pA2 in CPP (average reduction of 
79 ± 7%; p = 0.0291, ratio paired t test; n = 4; Figure 2b). 
Similar experiments were performed with A17 amacrines. 
For the A17 illustrated in Figure 2c, applying CPP markedly 
decreased the current noise, from an average of 5.7 pA2 in 
control to 0.5 pA2 in CPP (a reduction of 92%). For a total of 
three A17 amacrines, the average current noise in control was 
3.1 ± 1.3 pA2. This was reduced to 0.4361 ± 0.0045 pA2 in 
CPP (average reduction of 80 ± 7%; p = 0.0457, ratio paired 
t test; n = 3; Figure 2d). These results corresponded well to 
our previous findings (Veruki et al., 2019) and confirmed that 
gating of NMDAR channels contributed substantially to cur-
rent noise in the baseline condition of the present study.
We next recorded from AII and A17 amacrines in retinal 
slices prepared from tissue that had been incubated in bafi-
lomycin. These recordings were performed without blockers 
of neurotransmitter receptors. As illustrated by the examples 
in Figure 3a,b, incubation in bafilomycin almost completely 
eliminated synaptic currents and strongly reduced current 
noise (AII: Figure  3a, upper trace; A17: Figure  3b, upper 
trace), as expected from disrupted loading of synaptic ves-
icles by bafilomycin. This contrasted strongly with record-
ings from AII and A17 amacrines (also performed without 
blockers of neurotransmitter receptors) from tissue incubated 
under identical conditions, but without the addition of bafilo-
mycin (Figure 3a,b, lower traces). With the intracellular and 
extracellular solutions used here, the chloride equilibrium 
potential (ECl) was ~−60 mV. Accordingly, with Vh at either 
−60 mV (AIIs) or −70 mV (A17s), there was essentially no 
driving force for chloride current through GABA and/or gly-
cine receptor channels and the synaptic activity most likely 
corresponded to spontaneous excitatory postsynaptic cur-
rents mediated by AMPA- type glutamate receptors (Veruki 
et al., 2003). These results suggested that after incubation in 
bafilomycin, exocytosis of synaptic vesicles was not accom-
panied by release of neurotransmitter.
If the source of ambient glutamate that activates the ex-
trasynaptic NMDARs is generated by release from synaptic 
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vesicles, we would expect that blocking these receptors phar-
macologically should have little effect on membrane current 
noise in cells recorded from tissue incubated in bafilomycin. 
To test this, we measured current noise in AII amacrines after 
incubation in bafilomycin both before (control) and after add-
ing CPP. For these experiments, CNQX, strychnine, bicuc-
ulline, and TTX were included in the bath solution. For the 
AII amacrine illustrated in Figure 3c, adding CPP had almost 
no effect on the current noise, with an average of 2.8  pA2 
in control and 2.6  pA2 in CPP (a reduction of only 7%). 
For a total of five AII amacrines, the average current noise 
in control was 3.20  ±  0.97  pA2, not significantly different 
from 2.45 ± 0.72 pA2 in CPP (an average reduction of 16%; 
p = 0.3209, ratio paired t test; n = 5; Figure 3d). This re-
sult was, however, significantly different compared with the 
strong reduction of current noise evoked by CPP in AIIs from 
tissue that had not been incubated in bafilomycin (where the 
average reduction was 79%), as can be seen by comparing 
Figure 2b with Figure 3d (F1,7 = 6.246, p = 0.0410, two- way 
ANOVA). These results suggested that incubation in bafi-
lomycin, by blocking vesicular release of neurotransmitter, 
strongly reduced the level of extracellular glutamate available 
to activate the extrasynaptic NMDARs on AII amacrines.
In contrast, for A17 amacrines recorded from tissue that 
had been incubated in bafilomycin, the membrane current 
noise was still markedly reduced after adding CPP. For the 
A17 amacrine illustrated in Figure 3e, the noise was reduced 
from 1.5 pA2 in control to 0.4 pA2 in CPP (a reduction of 
72%). For a total of five A17 amacrine cells, the average cur-
rent noise in control was 1.05 ± 0.20 pA2, and in CPP, it was 
significantly reduced to 0.53 ± 0.12 pA2 (an average reduc-
tion of 46%; p = 0.0182, ratio paired t test; n = 5; Figure 3f). 
Furthermore, this reduction of current noise was not signifi-
cantly different from that evoked by CPP in A17s from tis-
sue that had not been incubated in bafilomycin (where the 
average reduction was 80%), as can be seen by comparing 
Figure 2d with Figure 3f (F1,6 = 4.528, p = 0.0761, two- way 
ANOVA). Thus, incubation in bafilomycin did not signifi-
cantly disrupt the source of glutamate that activates extra-
synaptic NMDARs on A17 amacrines. This suggested that 
the source of glutamate for these receptors is predominantly 
non- vesicular.
F I G U R E  2  Activation of NMDARs by ambient glutamate generates membrane current noise in AII and A17 amacrines. (a) Current of an 
AII amacrine recorded in whole- cell voltage clamp (Vh = −60 mV) in control (upper trace) and during application of CPP (20 µM) in the bath 
solution (lower trace) to block NMDARs. Here and later (unless otherwise noted), “control” refers to Mg2+- free bath solution that includes d- serine 
(100 µM) and blockers of AMPA, GABAA, and glycine receptors and voltage- gated Na
+ channels (see Section 2). Note reduction of current noise 
by CPP, suggesting activation of NMDARs by ambient glutamate in the control condition. Here and later, the identity of the cell (AII or A17) from 
which the recording was performed is indicated by the schematic figure next to the current traces. (b) Bar graph displays membrane current noise 
measured as variance (here and later, bars represent mean ± SEM) in AII amacrines (n = 4 cells) in control (without CPP; left bar) and in CPP 
(right bar). Here and later, data points for the same cell are connected by lines and the results from statistical comparisons between averages are 
indicated by n.s. (no significant difference, p > 0.05) or a single asterisk (*; statistically significant difference, p ≤ 0.05). (c) Current from an A17 
amacrine recorded in whole- cell voltage clamp (Vh = −70 mV) in control (upper trace) and during application of CPP (20 µM) in the bath solution 
(lower trace). Note reduction of current noise by CPP, suggesting activation of NMDARs by ambient glutamate in the control condition. (d) Bar 
graph displays membrane current noise measured as variance in A17 amacrines (n = 3 cells) in control and in CPP
(a) (b)
(c) (d)
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3.3 | Disruption of the glutamate- glutamine 
cycle reduces NMDAR activation in AII, 
but not A17 amacrines
Under normal conditions in the nervous system, a glutamate- 
glutamine cycle operates where glial cells take up glutamate 
from the extracellular environment, convert it to glutamine 
with the enzyme glutamine synthetase, and then release the 
glutamine, which is subsequently taken up by neurons and 
converted back to glutamate (reviewed in Schousboe, 2019). 
In the retina, glutamine synthetase is located exclu-
sively in Müller glial cells (Lewis et  al.,  1988; Riepe & 
Norenburg, 1977), and treatment with MSO leads to a rapid 
and complete redistribution of glutamate from neurons to 
Müller cells (Barnett et  al.,  2000; Pow & Robinson, 1994; 
Winkler et al., 1999). In hippocampal slices, inhibiting glu-
tamine synthetase with MSO has also been shown to redis-
tribute glutamate, resulting in a decrease of glutamate in 
neuronal terminals and an increase of glutamate in glial cells 
(Laake et al., 1995). Thus, MSO will both eliminate the abil-
ity of neurons to replenish the glutamate used for synaptic 
release and potentially increase the glutamate available for 
release from glial cells due to intracellular accumulation. 
We reasoned that if the extracellular glutamate that activates 
extrasynaptic NMDARs on AII and A17 amacrines was from 
a neuronal source, inhibiting glutamine synthetase with MSO 
would have an effect similar to bafilomycin (by decreasing 
the glutamate available to activate the receptors). However, if 
the NMDARs are activated by glutamate released from glial 
cells, inhibiting glutamine synthetase with MSO should not 
reduce the available glutamate and, thus, should not lead to a 
reduced activation of the receptors.
To test these predictions, we inhibited glutamine synthe-
tase by incubating pieces of retina in MSO for at least 2.5 hr 
(Le Meur et al., 2007; Wu et al., 2012) before preparing ret-
inal slices and recording from AII and A17 amacrines. As 
illustrated by the examples in Figure 4a,b, incubation in MSO 
almost completely eliminated synaptic currents and strongly 
reduced current noise in both cell types, in recordings with-
out blockers of neurotransmitter receptors (Figure 4a,b, upper 
traces). This contrasted strongly with similar recordings from 
AII and A17 amacrines incubated under identical conditions, 
but without the addition of MSO (Figure 4a,b, lower traces). 
This result was consistent with a disruption of the glutamate- 
glutamine cycle by MSO.
We next investigated the effect of blocking NMDARs in 
cells recorded from tissue incubated in MSO, by measuring 
membrane current noise before (control) and after adding 
F I G U R E  3  Depletion of neurotransmitter from synaptic vesicles with bafilomycin A1 reduces NMDAR activation in AII, but not A17 
amacrines. (a) Upper trace: current from an AII amacrine from tissue incubated with bafilomycin A1 (Baf A1; 4 µM) for >2.5 hr prior to slice 
preparation. Note lack of spontaneous postsynaptic currents (spPSCs) and low membrane current noise. Lower trace: current from a different AII 
amacrine recorded under identical conditions, but from tissue incubated without Baf A1. Note spPSCs and prominent current noise. (b) Upper trace: 
current from an A17 amacrine from tissue incubated with Baf A1 for >2.5 hr prior to slice preparation. Note lack of spPSCs and low current noise. 
Lower trace: current from a different A17 amacrine recorded under identical conditions, but from tissue incubated without Baf A1. Note spPSCs 
and prominent current noise. (c) Current from an AII amacrine from tissue incubated with Baf A1, both in control (without CPP; upper trace) and 
after adding CPP (20 µM) to the bath solution (lower trace). Note similar magnitude of current noise in the two conditions. (d) Bar graph displays 
membrane current noise measured as variance in AII amacrines (n = 5 cells) in control and in CPP. Note lack of effect of CPP on current noise. (e, 
f) same as (c, d), but for A17 amacrines (n = 5 cells). Note significant reduction of current noise by CPP in A17s from tissue incubated in Baf A1
(a) (b)
(c) (e)(d) (f)
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CPP. For these experiments, CNQX, strychnine, bicuculline, 
and TTX were included in the bath solution. For the AII ama-
crine illustrated in Figure 4c, from tissue incubated in MSO, 
adding CPP had almost no effect on the current noise, with an 
average of 1.0 pA2 in control and 0.8 pA2 in CPP. For a total 
of five AII amacrines, the average current noise in CPP was 
2.53 ± 0.95 pA2, slightly reduced, but not significantly differ-
ent from 3.3 ± 1.1 pA2 in control (p = 0.11418, ratio paired 
t test; n = 5; Figure 4d). However, the average reduction of 
current noise (24%) evoked by CPP in AIIs from tissue incu-
bated in MSO was significantly different from that evoked 
by CPP in AIIs from tissue not incubated in MSO (a 79% 
reduction in noise), as can be seen by comparing Figure 2b 
with Figure 4d (F1,7 = 6.274, p = 0.0407, two- way ANOVA). 
Thus, MSO disrupted the source of glutamate that activates 
extrasynaptic NMDARs of AII amacrines, suggesting that 
the source of glutamate is neuronal and not glial in origin.
In contrast, for A17 amacrines recorded from tissue incu-
bated in MSO, adding CPP markedly reduced the membrane 
current noise. For the A17 amacrine illustrated in Figure 4e, 
the noise was reduced from 6.2 pA2 in control to 1.0 pA2 in 
CPP (a reduction of 84%). For a total of six A17 amacrine 
cells, the average current noise in control was 4.0 ± 1.2 pA2, 
and in CPP, it was significantly reduced to 0.72 ± 0.24 pA2 
(an average reduction of 79%; p = 0.0008, ratio paired t test; 
n = 6; Figure 4f). This strong reduction of current noise was 
not significantly different from that evoked by CPP in A17s 
from tissue not incubated in MSO (where the average reduc-
tion was 80%), as can be seen by comparing Figure 2d with 
Figure  4f (F1,7  =  0.1740, p  =  0.6891, two- way ANOVA). 
Thus, depleting neuronal glutamate by blocking glutamine 
synthetase with MSO had no effect on the activity of the ex-
trasynaptic NMDARs on A17 amacrines. This strongly sug-
gested that the source of glutamate for these receptors is glial 
in origin.
Next, we considered that an MSO- evoked redistribution 
of glutamate from neurons to Müller glial cells (Barnett 
et al., 2000; Pow & Robinson, 1994; Winkler et al., 1999), 
could increase the glutamate accumulated in and released 
from the glial cells, and thus lead to an enhanced activation 
of NMDARs on A17 amacrines. An increased activation of 
NMDARs, however, could be prevented if glutamate trans-
porters are able to effectively buffer increased extracellular 
glutamate (Le Meur et al., 2007). To investigate this, we re-
peated the above experiments and recorded from A17 ama-
crines in tissue that had been incubated in MSO. For these 
recordings, CNQX, strychnine, bicuculline, and TTX were 
included in the bath solution. After establishing a baseline 
F I G U R E  4  Blocking glutamine synthetase with MSO reduces NMDAR activation in AII, but not A17 amacrines. (a) Upper trace: current 
from an AII amacrine from tissue incubated with MSO (5 mM) for >2.5 hr prior to slice preparation. Note lack of spPSCs and low current noise. 
Lower trace: current from a different AII amacrine recorded under identical condtions, but from tissue incubated without MSO. Note spPSCs and 
prominent current noise. (b) Upper trace: current from an A17 amacrine from tissue incubated with MSO for >2.5 hr prior to slice preparation. Note 
complete lack of spPSCs and low current noise. Lower trace: current from an A17 amacrine recorded under identical conditions, but from retinal 
tissue incubated without MSO. Note spPSCs and prominent current noise. (c) Current from an AII amacrine from tissue incubated with MSO, both 
in control (without CPP; upper trace) and after adding CPP (20 µM) to the bath solution (lower trace). Note similar magnitude of current noise in 
the two conditions. (d) Bar graph displays membrane current noise measured as variance in AII amacrines (n = 5 cells) in control and in CPP. Note 
lack of effect of CPP on current noise. (e, f) same as (c, d), but for A17 amacrines (n = 6 cells). Note significant reduction of current noise by CPP 
in A17 amacrines from tissue incubated in MSO
(a) (b)
(c) (d) (f)(e)
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of current noise, we blocked uptake of glutamate by adding 
TBOA, a non- selective, non- transported blocker of excit-
atory amino acid transporters (Shimamoto et  al.,  1998), to 
the bath solution. For the A17 illustrated in Figure 5a, TBOA 
evoked a large inward current (~70 pA) and a strong increase 
of current noise, from 9.1  pA2 in control to 38.4  pA2 in 
TBOA (an increase of ~320%; Figure 5a,b). Adding CPP (in 
the maintained presence of TBOA) blocked the increase of 
current noise, reducing it to a level (1.1 pA2) that was much 
lower than the baseline level observed before adding TBOA 
(Figure 5a,b). CPP also blocked the inward current evoked 
by TBOA, resulting in an apparent outward current relative 
to the baseline recorded before TBOA (Figure 5a). This sug-
gested that NMDARs were activated in the baseline condition 
and that the level of activation increased after blocking gluta-
mate uptake pharmacologically.
The difference between the maximum inward current 
during TBOA (relative to baseline) and the maximum out-
ward current during CPP (relative to baseline) corresponds 
to the total NMDAR- mediated current (INMDA; Figure  5a). 
For this cell, INMDA measured ~105 pA. Similar results were 
observed for a total of six A17s incubated in MSO. Adding 
F I G U R E  5  Incubation in MSO does not result in increased glutamate release from glial cells. (a) Series of 20- s epochs of current recorded 
from an A17 amacrine from tissue incubated with MSO (5 mM; >2.5 hr) before slice preparation. After establishing a baseline, TBOA (50 µM) 
was added to the bath solution (here and later, duration of drug application indicated by continuous or dashed horizontal line above current traces) 
to block uptake of glutamate. Note inward current (relative to baseline) and increased noise evoked by TBOA. Subsequently, CPP (20 µM) was 
added to the bath solution to block NMDARs. Note block of inward current and strong reduction of current noise by CPP. Here and later, black 
circles above recorded currents indicate epochs used to calculate averages for current amplitude and current noise for a given condition. Here and 
later, numbered data points (1, 2, and 3) correspond to current epochs displayed separately with expanded time axis. Here and in (d) vertical line 
marked INMDA is the difference between the maximum inward current (relative to basline) in TBOA and maximum outward current (relative to 
baseline) in CPP and corresponds to current activated by endogenous agonist (presumably glutamate) mediated by NMDA receptor channels. (b) 
Individual epochs of current recorded from A17 amacrine in (a); in control (1), in the presence of TBOA (2), and in the presence of TBOA + CPP 
(3). (c) Bar graph displays membrane current noise measured as variance in A17 amacrines (n = 6 cells) recorded from tissue incubated with MSO 
before slice preparation in control, in TBOA, and in TBOA + CPP. Note significant differences between noise in the three conditions. (d) Current 
amplitude in A17 amacrines (same cells as in c) measured in the same conditions as in (c): control, TBOA, and TBOA + CPP. Note inward current 
evoked by TBOA and subsequent block by CPP. (e) Bar graph displays INMDA (estimated as indicated in a and d) in A17 amacrine cells from tissue 
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TBOA significantly increased the average current noise from 
7.7 ± 1.6 pA2 in the baseline condition to 22.5 ± 3.4 pA2 (an 
increase of ~370%; Figure 5c; p = 0.0235, adjusted p value, 
one- way ANOVA followed by Tukey's multiple compari-
son test; n = 6). Adding CPP reduced the average noise to 
1.15 ± 0.16 pA2, a significant decrease from both the base-
line condition (75% reduction, p = 0.0221) and the TBOA 
condition (95% reduction, p  =  0.0035; adjusted p values, 
one- way ANOVA followed by Tukey's multiple comparison 
test; n = 6). For the same cells, TBOA evoked a net inward 
current of 57 ± 13 pA (range 13−94 pA) relative to control, 
from −45.4 ± 7.8 pA in control to −102 ± 12 pA in TBOA 
(p = 0.0166, adjusted p value, one- way ANOVA followed by 
Tukey's multiple comparison test; n = 6; Figure 5d). Adding 
CPP blocked the inward current evoked by TBOA and for the 
majority of cells also evoked an apparent outward current rel-
ative to baseline (Figure 5d). The average current after add-
ing CPP was −14 ± 11 pA, significantly different from the 
TBOA condition (p = 0.0055), but not significantly different 
from the control condition (p  =  0.1092, adjusted p values, 
one- way ANOVA followed by Tukey's multiple comparison 
test; n = 6; Figure 5d). The average INMDA for A17 amacrines 
from tissue incubated in MSO was 88 ± 16 pA (n = 6), not 
significantly different from INMDA for A17s that had not been 
exposed to MSO (67 ± 12 pA; n = 4; p = 0.3673, unpaired 
t test; Figure 5e). This suggested that if incubation in MSO 
increases the glutamate available for release from glial cells, 
it does not result in increased activation of NMDARs on A17 
amacrine cells. These results also suggested that incubation in 
MSO does not in itself block the activity of glutamate trans-
porters and, that for A17 amacrines, INMDA is independent of 
synaptically released glutamate. Taken together, these exper-
iments provide additional strong support for the hypothesis 
that NMDARs on A17s are activated by glutamate released 
from a glial source.
3.4 | Co- agonist binding 
sites are not saturated for NMDARs of AII or 
A17 amacrines
Unlike most neurotransmitter receptors, NMDARs re-
quire the binding of a co- agonist, either glycine or d- serine, 
for channel gating to occur (Johnson & Ascher,  1987; 
Kleckner & Dingledine, 1988; Mothet et al., 2000; Wolosker 
et  al., 1999). To explore the role of the co- agonist binding 
site for the NMDARs of AII and A17 amacrines, we first ad-
dressed whether the endogenous co- agonist binding sites are 
saturated in our preparation. To investigate this we recorded 
membrane current noise, first in a control condition without 
d- serine in the bath solution and then after adding d- serine 
(100 µM) to the bath solution. In these experiments, CNQX, 
bicuculline, strychnine, and TTX were included in the bath 
solution. For the AII amacrine illustrated in Figure 6a, the 
current noise increased from 15.0 pA2 in control to 25.9 pA2 
in d- serine (an increase of ~72%; each average calculated 
from four epochs, Figure 6a). The increase of noise can be 
seen more clearly for the representative epochs illustrated at 
an expanded scale in Figure 6b (1: control, 2: d- serine). For 
this cell, d- serine also evoked a small inward current relative 
to baseline (~3 pA). For a total of six AIIs tested, there was 
a significant increase of current noise from 21.2 ± 6.7 pA2 in 
control to 35 ± 11 pA2 in the presence of d- serine (an aver-
age increase of ~68%; p = 0.0163, ratio paired t test, n = 6; 
Figure  6c). d- serine did not, however, evoke a significant 
or consistent change in current amplitude, with a small in-
ward current observed for three cells and a small outward 
current for the three other cells (the average net change was 
4.6 ± 7.2 pA).
When A17 amacrines were tested in the same way, the re-
sults were similar to but much more pronounced than for the 
AIIs. For the A17 illustrated in Figure 6d, the current noise 
increased from 2.6  pA2 in control to 26.7  pA2 in d- serine 
(an increase of ~925%; each average calculated from two or 
three epochs as indicated; Figure 6d). The strong increase of 
noise can be seen more clearly for the representative epochs 
illustrated at an expanded scale in Figure 6e (1: control, 2: 
d- serine). The increase of noise was accompanied by a large 
inward current with both transient and sustained compo-
nents (~42 pA peak amplitude relative to the baseline level). 
Adding CPP (in the maintained presence of d- serine) blocked 
the increase of current noise, reducing it to a level (0.80 pA2) 
lower than the baseline level before d- serine (Figure 6d,e). 
CPP also blocked the inward current evoked by d- serine and 
resulted in a small outward current relative to the baseline 
recorded before d- serine (Figure 6d). That CPP reduced both 
the membrane noise and the inward current strongly suggests 
the presence of a baseline level of NMDAR- mediated activ-
ity in the absence of added d- serine. For a total of four A17s 
tested, there was a significant increase of current noise from 
3.5 ± 1.4 pA2 in control to 17.7 ± 6.2 pA2 in the presence 
of d- serine (an average increase of ~530%; p = 0.0151, ratio 
paired t test, n = 4; Figure 6f). Three of the cells could be held 
long enough to add CPP to the bath solution. For these cells, 
CPP reduced the current noise to 1.01 ± 0.49 pA2, a signifi-
cant reduction from the d- serine condition (p = 0.0400), but 
not the baseline condition (p  =  0.8632; adjusted p values, 
one- way ANOVA followed by Tukey's multiple comparison 
test; n  =  3; Figure  6f). For all A17s tested in this way, d- 
serine also evoked an inward current with transient and sus-
tained response components. The amplitude of the transient 
peak (relative to baseline) was 36 ± 13 pA (range 10– 55 pA). 
For the three cells tested with CPP, the inward current evoked 
by d- serine was completely blocked and, for two of the cells, 
CPP evoked an apparent outward current relative to base-
line. These results with CPP clearly suggested that both the 
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increase of current noise and the inward current evoked by 
d- serine were due to increased activation of NMDARs in A17 
amacrines.
The above experiments suggested that, for both AII and 
A17 amacrines, the endogenous co- agonist binding site for 
NMDARs was not saturated, opening up the possibility 
F I G U R E  6  Co- agonist binding sites for NMDARs on AII and A17 amacrines in retinal slices are not saturated. (a) Series of 20- s epochs of 
current recorded from an AII amacrine. After establishing a baseline, the NMDAR co- agonist d- serine (100 µM) was added to the bath solution. 
Note moderate increase of current noise and small inward current (relative to the baseline) evoked by d- serine. (b) Individual epochs of current 
recorded from AII amacrine in (a); in control (1) and in the presence of d- serine (2). (c) Bar graph displays membrane current noise measured as 
variance in AII amacrines (n = 6 cells) in control and in d- serine. Note significant increase of noise evoked by d- serine. (d) Series of 20- s epochs 
of current recorded from an A17 amacrine. After establishing a baseline, d- serine (100 µM) was added to the bath solution. Note marked increase 
of noise and inward current evoked by d- serine. Subsequently, CPP (20 µM) was added to the bath solution to block NMDARs. Note apparent 
outward current (relative to baseline) and strong reduction of current noise evoked by CPP. (e) Individual epochs of current recorded from A17 
amacrine in (d); in control (1), in the presence of d- serine (2), and in the presence of d- serine + CPP (3). (f) Bar graph displays membrane current 
noise measured as variance in A17 amacrines (n = 4) in control, in d- serine, and in d- serine + CPP (only three of the cells were recorded with CPP 
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that modulation of co- agonist levels has the potential to 
regulate the activation of these receptors (cf. Kalbaugh 
et  al.,  2009). The d- serine- evoked increase of current 
noise and inward current was considerably larger for A17s 
than for AIIs, possibly suggesting that the endogenous co- 
agonist for A17s is maintained at a lower level than that for 
AIIs. It is difficult, however, to make a direct comparison 
because the total number of receptors is likely to be higher 
for A17s, given the larger total length of processes for 
this wide- field amacrine compared with the narrow- field 
AII. Related to this, the smaller dendritic trees and shorter 
branches of the AII likely result in a lower extent of elec-
trotonic filtering, with increases of NMDAR- mediated 
channel gating more easily detected as increased current 
noise, before becoming strong enough to be accompanied 
by a clear increase in inward current (relative to baseline). 
It is also important to note that in the retinal slice prepara-
tion, as used here, levels of endogenous co- agonists could 
be lower than under normal, physiological conditions (in 
situ) because of washout.
F I G U R E  7  d- serine is the endogenous co- agonist for NMDARs on AII amacrines. (a) Series of 20- s epochs of current recorded from an AII 
amacrine. Here and in (d), d- serine was not included in the bath solution. After establishing a baseline, the enzyme d- amino acid oxidase (DAAO; 
0.29 U/ml) was added to the bath solution to degrade any endogenous d- serine. Note reduction of current noise following application of DAAO. (b) 
Individual epochs of current recorded from AII amacrine in A; in control (1) and in the presence of DAAO (2). (c) Bar graph displays membrane 
current noise measured as variance in AII amacrines (n = 5 cells) in control and in DAAO. Note significant decrease of noise evoked by DAAO. 
(d) Series of 20- s epochs of current recorded from an A17 amacrine. After establishing a baseline, the enzyme d- amino acid oxidase (DAAO) was 
added to the bath solution. Note similarity of current noise before and after application of DAAO. (e) Individual epochs of current recorded from 
A17 amacrine in (d); in control (1) and in the presence of DAAO (2). (f) Bar graph displays membrane current noise measured as variance in A17 
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3.5 | d- serine is the likely co- agonist at 
extrasynaptic NMDARs of AII amacrine cells
It has been proposed that d- serine primarily acts at synap-
tic NMDARs and glycine primarily acts at extrasynaptic 
NMDARs (Papouin et al., 2012), but there is also evidence 
that either or both of these co- agonists can act on NMDARs 
throughout the CNS, with no preference for synaptic versus 
extrasynaptic receptors (Li et al., 2013; Mothet et al., 2015; 
Rosenberg et al., 2013). For the NMDARs on AII and A17 
amacrines, which appear to be exclusively extrasynaptic, 
there is no information about which co- agonists are involved, 
or whether there may be a preferred co- agonist for either re-
ceptor population based on endogenous availability.
To investigate whether d- serine or glycine might be the 
physiologically relevant co- agonist for NMDARs on AII or 
A17 amacrines, we performed a series of recordings with the 
enzyme DAAO that degrades endogenous d- serine (Dixon & 
Kleppe, 1965; Molla et al., 2006). If treatment with DAAO 
decreases membrane current noise, it would suggest that d- 
serine is the predominant endogenous co- agonist at the cor-
responding NMDARs (Li et al., 2013; Mothet et al., 2015; 
Panatier et al., 2006; Papouin et al., 2012). For these experi-
ments, d- serine was not included in the bath solution, which 
contained CNQX, bicuculline, strychnine, and TTX. For the 
AII illustrated in Figure 7a, adding DAAO to the bath solu-
tion (0.29  U/ml) resulted in a slowly developing decrease 
of current noise, from 14.8 pA2 in control to 3.7 pA2 after 
~20 min in DAAO (a reduction of ~74%; each average cal-
culated from four epochs, Figure 7a). The strong decrease of 
noise can be seen more clearly for the representative epochs 
illustrated at an expanded scale in Figure 7b (1: control, 2: 
DAAO). The noise decrease was accompanied by a slowly 
developing outward current (~12  pA peak amplitude) rel-
ative to the baseline. For five AIIs, there was a significant 
reduction of current noise from 16.1 ± 2.7 pA2 in control to 
4.7 ± 1.1 pA2 after ~20 min in DAAO (an average reduction 
of 65%; p = 0.0224, ratio paired t test, n = 5; Figure 7c). 
For the same cells, the average outward current (relative 
to baseline) evoked by DAAO was 14.1 ± 5.0 pA (with all 
cells displaying an outward current relative to baseline). 
Thus, enzymatic degradation of d- serine was accompanied 
by marked reduction in current noise for AII amacrines, 
strongly suggesting that d- serine is the endogenous co- 
agonist at NMDARs on these cells.
In contrast, for A17 amacrines tested in the same way, 
DAAO had no clear effect on membrane current noise. For 
the A17 illustrated in Figure  7d, the noise in control was 
5.7 pA2, and after ~20 min in DAAO, it was 4.7 pA2 (a re-
duction of ~19%; each average calculated from four epochs, 
Figure  7d). The relatively similar noise level in the two 
conditions can be observed for the representative epochs 
illustrated at an expanded scale in Figure 7e (1: control, 2: 
DAAO). For this cell, the difference in the current magnitude 
between control and DAAO was only 1.5 pA (Figure 7d). For 
six A17s, there was no significant difference between the cur-
rent noise in control (4.24  ±  0.66  pA2) and after ~20  min 
in DAAO (3.90 ± 0.99 pA2; p = 0.2888, ratio paired t test, 
n  =  6; Figure  7f). For the same A17 cells, adding DAAO 
was accompanied by minor changes in the current magnitude. 
Five cells displayed a small outward current (7.4 ± 2.9 pA), 
and one cell displayed a small inward current (3.8 pA) rela-
tive to baseline. The lack of effect of DAAO on the current 
noise for A17 amacrines suggested that d- serine is not likely 
to be the predominant endogenous co- agonist for NMDARs 
on these cells. Rather, it suggests that glycine is the major 
endogenous co- agonist.
4 |  DISCUSSION
AII and A17 amacrine cells are the main inhibitory interneu-
rons of the rod pathway microcircuit, and each cell type 
expresses NMDARs with an exclusively extrasynaptic loca-
tion. NMDARs of AII amacrines contain GluN2B subunits, 
whereas those of A17 amacrines contain GluN2A subunits 
(Veruki et al., 2019). As the specific GluN2 subunit strongly 
influences the functional properties of NMDARs (Paoletti 
et al., 2013), this suggests that these receptors are exploited 
for different purposes in AII and A17 amacrines which re-
ceive simultaneous synaptic glutamatergic input from rod 
bipolar cells. Here, we reveal that the sources of glutamate 
and the endogenous co- agonists that activate these recep-
tor populations are also different, adding to their divergent 
characteristics. Our results suggest that NMDARs on AIIs 
are activated by glutamate that arises from vesicular release 
from neurons, and that d- serine is the endogenous co- agonist. 
This contrasts with A17s, where the source of glutamate is 
predominantly non- vesicular, originating from glial cells, 
and the endogenous co- agonist is likely to be glycine. These 
results are summarized by the schematic in Figure 8. Below 
we discuss the basis for our interpretations and their func-
tional implications.
4.1 | Different sources of glutamate for 
extrasynaptic NMDARs
In general, synaptic receptors are exclusively activated by 
neurotransmitter released from directly apposed, morpholog-
ically specialized presynaptic terminals. For extrasynaptic 
receptors, the source of neurotransmitter is more compli-
cated and can encompass both neurotransmitter originating 
from synaptic spillover at varying distances from the recep-
tors and neurotransmitter originating from non- neuronal 
sources. Extracellular glutamate originates from vesicular 
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release from neurons and from vesicular and non- vesicular 
release from glial cells (Hamilton & Attwell,  2010). The 
concentration of extracellular glutamate is estimated to be 
from 0.03 to 3 µM (Vizi et al., 2010), a level sufficient to 
activate NMDARs (Traynelis et  al.,  2010). For the extra-
synaptic NMDARs on AII and A17 amacrines, potential 
sources of glutamate include spillover following synaptic 
release from rod and cone bipolar cells (Veruki et al., 2006; 
Wersinger et al., 2006) and release of glutamate from glial 
cells (Bringmann et al., 2006).
We manipulated extracellular glutamate by blocking 
vesicular uptake with bafilomycin or by blocking the en-
zymatic conversion of glutamate to glutamine within glial 
cells with MSO. Bafilomycin will reduce the concentration 
of ambient glutamate originating from vesicular release 
(from neurons and glia). MSO will reduce the concentra-
tion of ambient glutamate originating from neurons, but 
not from glia. For the NMDARs on AII amacrine cells, 
incubation in bafilomycin or MSO resulted in decreased 
NMDAR- mediated current noise, strongly suggesting that 
the source of glutamate is both vesicular and neuronal. For 
glutamate that originates from non- vesicular release from 
glia, neither pharmacological agent should lead to a signif-
icant decrease of the ambient concentration of glutamate 
and, thus, little change in NMDAR- mediated current noise 
would be expected. This is consistent with our observations 
for A17 amacrines, suggesting that NMDARs on these cells 
are activated by non- vesicular glutamate released from glial 
cells. A third outcome, when using bafilomycin and MSO, 
could reveal that the source of glutamate was due to vesicu-
lar release from glial cells. In this case, bafilomycin would 
reduce the available glutamate (and reduce NMDAR- 
mediated activity), but MSO would not. However, this was 
not observed in our study.
Glial sources of glutamate have been shown to activate 
extrasynaptic NMDARs in hippocampal CA1 pyramidal 
cells (Fellin et  al.,  2004; Gómez- Gonzalo et  al.,  2018; Le 
Meur et  al.,  2007). In contrast, spillover of glutamate re-
leased synaptically from neurons has been shown to acti-
vate extrasynaptic NMDARs on granule cells in the dentate 
gyrus (Dalby & Mody, 2003), retinal ganglion cells (Chen & 
Diamond, 2002), and CA1 pyramidal cells (Diamond, 2001). 
For AII and A17 amacrines, the functional significance of 
distinct sources of glutamate is not readily apparent, but sug-
gests that the extrasynaptic NMDARs on these neurons are 
activated independently of each other.
F I G U R E  8  Different sources of glutamate and different 
endogenous co- agonists activate NMDARs on AII and A17 amacrines. 
(a) Schematic illustration of the major components of the classical rod 
pathway microcircuit in mammalian retina: A17 amacrine (green), 
AII amacrine (yellow), rod bipolar cell (RBC; medium blue), OFF- 
cone bipolar cell (OFF- CBC; light blue), and ON- cone bipolar cell 
(ON- CBC; dark blue). A Müller glial cell (light red) is also included. 
Photoreceptors are omitted for simplicity. (b) Magnified view of 
cellular interactions mediated by neurotransmitters, neurotransmitter 
receptors, and transporters in region of (a) demarcated by dashed 
rectangle. Synaptic release of glutamate from RBC (solid black 
arrows) activates postsynaptic Ca2+- permeable AMPA receptors 
on A17 and AII amacrines. Glutamate diffusing into neuropil after 
synaptic release (dashed black arrows) activates extrasynaptic 
NMDARs on AII amacrines and is removed by uptake into Müller 
glial cells. Müller glial cells release glutamate (dotted black arrow) 
via unknown non- vesicular mechanism(s). Extrasynaptic NMDARs 
of A17s are activated by ambient glutamate from a glial source and 
glycine (from an unknown neuronal source) as the endogenous co- 
agonist. Extrasynaptic NMDARs of AIIs are activated by ambient 
glutamate originating from a neuronal source, with d- serine, released 
from Müller glial cells (small black arrow) or potentially astrocytes 
in the nerve fiber layer, as the endogenous co- agonist. Many details 
have been omitted for simplicity. For example, AII amacrines express 
extrasynaptic NMDARs not only on their distal arboreal dendrites, but 
also on proximal arboreal and lobular dendrities. In addition, neuronal 
sources of glutamate correspond not only to glutamate released from 
RBCs, but also from ON- and OFF- cone bipolar cells
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4.2 | Endogenous co- agonists for 
extrasynaptic NMDARs
Both d- serine and glycine have been identified as co- 
agonists at NMDARs, but it is generally not known 
whether one or the other fulfills that role for a specific 
NMDAR population under physiological conditions 
(Mothet et al., 2015). The suggestion that d- serine primar-
ily acts at synaptic GluN2A- containing receptors, whereas 
glycine primarily acts at extrasynaptic GluN2B- containing 
receptors (e.g., Le Bail et al., 2015; Papouin et al., 2012), 
seems to be violated by multiple exceptions, including the 
lack of correspondence between the molecular identity of 
the GluN2 subunit and the synaptic versus extrasynaptic 
location (e.g., Panatier et  al.,  2006). GluN2A- containing 
NMDARs have a slightly higher affinity for d- serine and 
an approximately tenfold lower affinity for glycine than 
GluN2B- containing NMDARs (Kutsuwada et  al.,  1992; 
Priestley et al., 1995). These differences in affinity are rel-
atively small, however, and the status of d- serine or glycine 
as the endogenous co- agonist for a given receptor popula-
tion may well depend on other factors such as temporal and 
spatial availability related to release and uptake (Mothet 
et al., 2015).
d- serine is synthesized by the enzyme serine racemase 
and can be released by both neurons (glutamatergic and 
GABAergic) and glia (Coyle et al., 2020). In the retina, how-
ever, d- serine and serine racemase have only been detected in 
Müller glial cells and in astrocytes in the nerve fiber layer, but 
not in neurons (Stevens et al., 2003; Williams et al., 2006). In 
our experiments, enzymatic degradation of d- serine markedly 
reduced NMDAR- mediated noise for AII amacrines, strongly 
suggesting that d- serine is the endogenous co- agonist for 
the NMDARs on these cells. In contrast, for A17 amacrines 
recorded in the same conditions, degrading d- serine had no 
effect on NMDAR- mediated noise, suggesting that glycine, 
rather than d- serine, is likely to be the predominant endoge-
nous co- agonist.
Glycine would seem to be readily available in the ret-
ina, as ~50% of amacrine cells are glycinergic. Levels of 
extracellular glycine are tightly regulated in the retina by 
glycine transporters (GlyTs) that are exclusively located 
on glycinergic amacrine cells, including the AII (Menger 
et al., 1998; Pow & Hendrickson, 1999). There is no evi-
dence that glia in the retina either take up or release gly-
cine (Reye et  al.,  2001). Synaptically released glycine 
is thought to be the co- agonist at synaptic NMDARs on 
retinal ganglion cells (Kalbaugh et al., 2009), and the ac-
tivation of GlyT1 has been shown to regulate NMDAR ac-
tivity in ganglion cells (Reed et al., 2009). Although our 
interpretation that glycine is the co- agonist at NMDARs 
on A17s is reasonable, direct evidence for this remains to 
be obtained.
4.3 | Activation of extrasynaptic NMDARs 
on A17 amacrines
The source of non- vesicular glutamate that plays the pre-
dominant role in activating NMDARs on A17 amacrines 
remains unkown, but based on our results with MSO, it is 
reasonable to speculate that it corresponds to glial cells. A 
number of different mechanisms have been proposed for 
non- vesicular release of glutamate from astrocytes, including 
cystine- glutamate exchange (Baker et  al.,  2002) and efflux 
of cytosolic glutamate through either gap junction hemichan-
nels (e.g., Ye et al., 2003), the conductance pore of P2X7 re-
ceptors (e.g., Duan et al., 2003), or volume- sensitive organic 
anion channels (Kimelberg et  al.,  1990; Seki et  al.,  1999). 
In addition, under pathological conditions like ischemia, 
there is evidence for release via reversal of glutamate trans-
porters (Rossi et  al.,  2000). In the mammalian retina, the 
relevant glial cells are Müller cells and conventional astro-
cytes (in the nerve fiber and ganglion cell layers; Stone & 
Dreher, 1987). Müller cells span the entire thickness of the 
retina and have the highest glutamate uptake capability in this 
tissue (Rauen et  al.,  1998). There is evidence that, at least 
under some conditions, Müller cells can release glutamate via 
both vesicular and non- vesicular mechanisms (Reichenbach 
& Bringmann, 2013), both of which can be Ca2+- dependent 
(Slezak et al., 2012).
The processes of Müller cells are expected to be in close 
contact with the dendrites of both AII and A17 amacrines, 
but we are unaware of data that could suggest a differential 
localization of relevant molecular mechanisms within subcel-
lular compartments of Müller cells that would indicate a dif-
ferential relationship with either neuron. For astrocytes in the 
nerve fiber and ganglion cell layers, there also seems to be a 
paucity of relevant data, but the proximity of the processes of 
these cells to the dendritic processes of A17 amacrine cells in 
stratum 5 of the inner plexiform layer is intriguing.
4.4 | Functional roles for extrasynaptic 
NMDARs on AII and A17 amacrines
Previous work from our laboratory suggests that GluN2B- 
containing NMDARs on AII amacrines are co- localized with 
the gap junction protein connexin 36 (Veruki et  al.,  2019; 
see also Kothmann et al., 2012), supporting the hypothesis 
that the electrical synapses these cells make with each other 
and with ON- cone bipolar cells (Veruki & Hartveit, 2002a, 
2002b) can be modulated by NMDAR activation (Kothmann 
et  al.,  2012). A neuronal source for the glutamate that ac-
tivates these receptors suggests a mechanism that links 
gap junction modulation to changes in neuronal activity 
that impact levels of extracellular glutamate. Release of d- 
serine from retinal glial cells can also be modulated in an 
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activity- dependent manner, via activation of non- NMDARs 
(Sullivan & Miller, 2010) and by light stimulation (Gustafson 
et al., 2015; Sullivan et al., 2011).
A17 amacrine cells provide feedback inhibition to the 
axon terminals of rod bipolar cells through release of GABA 
(Chávez et  al.,  2006; Hartveit,  1999). We have previously 
demonstrated that activation of NMDARs can increase the 
excitability of A17 amacrines and enhance the inhibition of 
rod bipolar cells (Veruki et al., 2019). It is not clear, however, 
why a non- neuronal source of glutamate (coupled with a neu-
ronal source of the co- agonist glycine) might be functionally 
relevant for the activation of these NMDARs which can mod-
ulate the feedback inhibition.
Although the absolute magnitude of membrane current 
noise appears larger in AIIs than in A17s, both in control 
and after blocking NMDARs with CPP, the relative noise 
reduction evoked by CPP (without treatment with bafilomy-
cin or MSO) is quite similar for the two cell types (~80% 
block). The most likely explanation for the different noise 
levels (with or without blocked NMDARs) is the difference 
in intrinsic properties of these cell types, specifically their 
different morphological properties and electrotonic structure. 
For the wide- field A17 amacrines, with their long and thin 
processes, the extent of electrotonic (low- pass) filtering is 
expected to be much stronger than for the AII amacrine cells.
Even though GluN2A and GluN2B subunits have been lo-
calized to different regions of the dendritic trees of A17 and 
AII amacrine cells, respectively, our understanding of their 
exact subcellular distribution is incomplete. Further experi-
mental work to investigate the subcellular distribution of the 
specific subunits, the cellular correlates (as well as the con-
ditions and mechanisms of release) of the different sources 
of glutamate, and the functional consequences of activating 
extrasynaptic NMDARs on AII and A17 amacrines, is clearly 
required.
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